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The brain is the most compartmentalized organ. It is also highly aerobic. Because nerve cells grow but do not regenerate, the brain is the organ best
suited for the accumulation of metabolic errors colocalized in specific areas of the brain over an extended period. Alzheimer's disease (AD) is primar-
ily a neurological disorder of the elderly. It is suggested that this disorder results from the accumulation of such errors, and that AD onset aluminum
and iron contribute to but do not necessarily initiate the onset of the disease. In vitro and in vivo evidence summarized here suggests that this is
effected by interfering in the utilization of glucose and glucose-6-phosphate, and sequestration of iron by ferritin. 3,Bamyloid precursor proteins (3,-
APPs) are normal components of the human brain and some other tissues. Proteolysis of these, presumably by serine proteases, generates a 39 to
42 amino acid long peptide, the a-amyloid (f,-AP). In AD brains, ,B-AP aggregates into plaque, the hallmark of AD brains. Some of the a-APPs also
contain a 56 amino acid long segment which inhibits serine proteases. We show that in vitro, at pH 6.5, aluminum activates ,Bchymotrypsin 2-fold
and makes it dramatically resistant to protease inhibitors such as bovine pancreatic trypsin inhibitor (bPTI) or its mimic present in the fVamyloid pre-
cursor proteins (,B-APPs). Iron and oxygen are reported to favor cross-linking of ,-AP in vitro. Because iron and ferritin are components of neurotic
plaques, and acidic pH are reported in AD brains, we suggest that deregulation of iron and aluminum homeostasis permit their colocalization, and
contribute to the accumulation of metabolic errors leading to neuronal disorders including the formation of AD (senile) plaques. - Environ Health
Perspect 102(Suppl 3):207-213 (1994)
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Introduction
Alzheimer's disease (AD) is an age-associ-
ated dementia characterized by altered
memory, cognition, and behavior. In AD,
nerve cells in the specific areas ofthe brain
degenerate. Theories contributing to AD
include decreased cholinergic innervation
defective protein synthesis, defective pro-
tein turnover, and aluminum toxicity (1).
None are unequivocally proved or ruled
out. Indeed, to date, the observed differ-
ences in normal and AD brain are quanti-
tative rather than qualitative, but a search
for a single biochemical event initiating
AD has been unsuccessful. This is true
even of the most current suspect, the amy-
loid plaques; the aggregates of the 3-amy-
loid peptides (,B-AP) generated by the
proteolysis of the ,B-amyloid precursor pro-
teins (P-APPs) (2).
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An adult brain weighs between 1.2 and
1.5 kg, but utilizes 20% ofthe oxygen con-
sumed by the body. This highly aerobic tis-
sue uses glucose as a sole or major source of
energy. The requirement for glucose is very
high-120 g/day, compared to 190 g for
the entire body (3). The brain is also a
highly compartmentalized organ; the use of
glucose is area specific and stimuli depen-
dent. For example, the areas of the brain
using glucose in response to visual stimuli
are distinct from those using glucose in
response to auditory stimuli (4).
Furthermore, unlike other tissues, brain
cells do not multiply or regenerate. Thus,
this vital organ is also well suited for the
accumulation of toxins such as aluminum
and also of metabolic errors which may
result from such accumulation.
Solution chemistry of aluminum is
quite complex. Martin has suggested that
AI(III) is the biologically relevant species
and, based on its affinity constants for cit-
rate and transferrin as well as their circulat-
ing concentrations in vivo, these two
compounds are primarily responsible for
the chelation and transport of aluminum
(5). Regardless of the vehicle used for
transporting aluminum, it is generally
agreed that the concentration ofaluminum
in AD brains is high and that the distribu-
tion of aluminum within the brain is
nonuniform (6-8). Despite highly sensi-
tive techniques for quantifying focal con-
centrations of brain aluminum, some
researchers dispute the role ofaluminum in
AD and some dispute even the elevated
levels of aluminum in AD brains (9).
Nevertheless, several reports acknowledge
that aluminum may play a role in AD
(10).
We hypothesized that a critical mass of
metabolic errors colocalized in specific
areas of the brain is essential to produce a
neurological disorder such as AD.
Aluminum, a recognized neurotoxin, par-
ticipates in formulating this critical mass
by interfering in the metabolism of glu-
cose, iron and proteolytic processing of P-
APPs. Evidence obtained in our laboratory
supports this hypothesis. It is summarized
below.
Aluminum and Glucose
Metabolism
Glucose enters glycolysis as glucose-6-
phosphate (G6P). This reaction, catalyzed
by hexokinase, requires ATP and Mg(II).
In the brain, the enzyme is membrane
bound and the activity is latent. The acti-
vation requires its release from the mem-
brane. This then is the first step in glucose
consumption. Aluminum (III) binds to
ATP 10 times more tightly than does
Mg(II). Thus, in vitro, the concentration of
aluminum as low as 160 nM inhibits hex-
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Figure 1. Effects ofaluminum on human and pig brain G6PD isozymes and human erythrocyte 6-phosphogluconate dehy-
drogenase. The isozymes were incubated with 5 pM AIC13 in 25 mM HEPES, pH 7.0, at 23°C. At different times, an
aliquot was withdrawn and assayed for enzyme activities. Data are percentages ofvalues forthe controls. The specific
activities (pmole NADPH formed/mg of protein/min) of various preparations were as follows: human G6PD isozyme 1,
210; human G6PD isozyme 11, 52; pig G6PD isozyme 1, 50; and pig G6PD isozyme 11, 201. The specific activity of 6-phos-
phogluconate dehydrogenase was as follows: human isozyme 11, 21; pig isozyme 11, 51; and human erythrocyte, 48. (A):
G6PD activity of human (*) and pig (o) brain isozyme 1. (B G6PD activity of human (.) and pig (o) brain isozyme 11. Open
and solid squares indicate 6-phosphogluconate dehydrogenase activity of human and pig brain isozyme 11, respectively.
Triangles indicate 6-phosphogluconate dehydrogenase activityfrom human erythrocytes (14).
okinase (11). In view of this, one would
anticipate that Al(III) would inhibit all
ATP-dependent reactions. However, such
is not the case because glucokinase and
phosphofructokinase are unaffected by
Al(III), whereas pyruvate kinase is acti-
vated (12).
In the brain, 80 to 85% ofthe glucose-
6-phosphate is used in glycolysis, and the
remaining 15 to 20% is used by the hex-
osemonophosphate shunt which generates
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Figure 2. Reverse-phase HPLC of human brain ferritin
subunits. One mg of brain ferritin in 0.5 ml of water was
dissociated by incubation with acetic acid (67%), thiogly-
colic acid (5%) in a final volume of 0.86 ml on ice for 16 hr
followed by dialysis against 0.1% trifluroacetic acid (TFA)
and lyopholized, resuspended in 0.1% TFA, and injected
onto a Vydac C18 reverse-phase column connected to a
Waters dual pump HPLC. The solvent system employed
was solventA-0.1% TFA inwater; solvent 8-0.1% TFA in
80% acetonitrite. Flow rate = 1 ml/min. Eluted fractions
were monitored at 220 nm. Fractions were pooled,
lyopholized and rechromatographed. They ran true(35).
ribose-5-phosphate, CO2, and two mole-
cules of NADPH. Four enzymes that par-
ticipate in this process are G-6-P
dehydrogenase (G6PD), lactonase, 6-P-
gluconate dehydrogenase, and phospho-
pentose isomerase.
G6PD from the brain is a tetramer
composed of four identical molecular
weight (57,000) subunits but two types of
amino acid sequences. Therefore, elec-
trophorograms of the homogenates of
brain from human or pig show five bands
of enzyme activity. Two ofthese have been
purified to near homogeneity from pig and
human brain (13). Isozyme I has only
G6PD activity, whereas isozyme II also has
6-phosphogluconate dehydrogenase activ-
ity. Significantly, the G6PD activity of
both isozymes were inhibited by Al(III)
(Figure 1). The inactive protein bound a
total of four molecules of aluminum, one
per subunit. The circular diachroism stud-
ies showed that the aluminum-enzyme
complex was more randomly coiled than its
native counterpart. Bound metal ion was
nondialyzable, even in the presence of
EDTA. However, sodium fluoride or trans-
ferrin removed the bound metal ion and
restored full activity (KDAI = 2-3 1M) (14).
Thus, unlike hexokinase, aluminum bound
to the protein and produced an inactive
enzyme.
In the brain, the shunt pathway is asso-
ciated almost exclusively with myelineated
tissue, and the activity varies with the
degree of myelineation (15). Because the
synthesis of fatty acids requires NADPH,
this close association is functionally advan-
tageous.
The rate-limiting step in glycolysis is
the modulation of phosphofructokinase
and fructose-1,6-bisphosphatase activities
by fructose-1,6-bisphosphate, ATP, and
fructose-2,6-bisphosphate. However, recent
studies have shown that in the brain, the
initial modulator is ribose-1,5-bisphos-
phate (16). Reduced supply of ribose-5-
phosphate resulting from the aluminum-
mediated reduction in production of
NADPH and ribose-5-phosphate would
produce a focal deficit of the key compo-
nent essential for myelin synthesis as well
as for regulation ofglycolysis.
Experimental metal toxicity can be pro-
duced by injecting very high concentra-
tions of the toxicant. While such studies
save time, physiologically relevant metal
toxicity results from prolonged exposure to
a chronic level ofthe toxicant. We reported
that brain homogenates of rats fed 100 pM
AlCl 6H20 in the drinking water for 1
year had about a 25% reduced activity of
hexokinase and G6PD (17). Examination
ofthe sections ofthe brains of rats similarly
exposed to AlC13.6H20 for two years also
showed between 15% and 20% reduction
of glucose metabolism in several areas of
the brain (18). The results approached sta-
tistical significance only for the ventral pal-
ladium and temporal cortex. Although
more animals were essential to establish a
statistically significant difference, the
observed reduction is compatible with the
reported aluminum-mediated impaired
metabolism ofglucose by rat brains in vitro
(19) and reduced hexokinase in AD brains
(20).
Iron and Brain Metabolism
In higher organisms, iron bound to trans-
ferrin and stored in ferritin accounts for
more than 90% ofthe total nonheme iron
(21). Both proteins also sequester other
metal ions, including aluminum (22).
Intracellular concentration ofiron regulates
the synthesis of ferritin and the stability of
the transferrin receptors. When the cellular
concentration of iron is high, the available
ferritin mRNA is utilized more efficiently
and at lower concentrations of iron, the
transferrin receptor mRNA is more stable;
and, therefore, more transferrin receptors
are available for iron transport. This regula-
tion is due to a conserved sequence of 28
nucleotides at the 5'untranslated region
(5'-UTR) of ferritin mRNA and at the 3'-
UTR ofthe transferrin receptor (23).
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Figure 3. Schematic comparison of the three clones for the ferritin H chain in human tissue, showing the number of
nucleotides in each message. Note: the message in the brain contains a unique 279 bp atthe 3'-UTR. Fetal brain has 54
nucleotides at the 5'-UTR which are absent in the liver message. In the brain, the larger message (1.4kb) is nine times
more abundantthanthe smaller, liver-type message. Inthe liver, the smaller message isthreetimes moreabundantthan
the larger message.
Transferrin(s), a family ofglycoproteins
ofmw 80,000 is a single polypeptide chain.
It has two metal-binding sites, one each at
the N- and C-terminal end. It is the major
serum protein that transports iron. It also
binds other metal ions including aluminum
(24,25). The stability constants for the N-
and C-sites are not identical. In vivo, even
under extreme iron overload, only 30% of
the total iron binding sites are occupied by
iron (21). Because a convenient radioactive
isotope of aluminum is not available in
vitro, radioactive gallium, 67Ga(III), is
often used as an aluminum mimic and the
data extrapolated to in vivo situations.
Farrer et al. showed that transferrin from
the sera ofAD patients bound less gallium
(and, therefore, less aluminum by infer-
ence) than the age-matched controls. They
suggested that in AD patients transferrin
binds less aluminum and, therefore, more
serum aluminum is available for transport
to the brain (26). This potentially attrac-
tive idea is controversial because the same
observed reduced gallium binding would
result if the presumed iron-free sites were
actually occupied by aluminum.
Furthermore, the more recent data suggests
that in vivo aluminum and gallium are not
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Figure 4. Schematic representation of ,B-APP. Black verti-
cal bar is the plasma membrane which separates the
cytoplasmic and extracellular region. Various segments of
the )-APP (horizontal bar) are 2, cysteine rich region; 3,
acidic rich; 4, bPTI-like protease inhibitory segment; 5, gly-
cosylated region; 6, ,B-AP; 7, cytoplasmic region.
transported by the same mechanism (27).
In this respect, the data by Connor et al.
are noteworthy (28). These workers
showed that the access ofaluminum to var-
ious areas of the brain is probably via the
transferrin-mediated receptor system; they
suggested that this system may also regulate
the transport ofother metal ions. They also
noted that although transferrin and its
receptors are present throughout the brain,
their distribution in the central nervous
system is not uniform (28). These observa-
tions further underscore the possibility of a
colocalization of metal ions producing
metabolic errors leading to neurological
disorders.
Transferrin in the serum delivers its
metal ions to the brain via a transferrin-
receptor mediated system. The olfactory
system seems to have its own transferrin-
like protein, thus gaining direct access to
the brain (DP Perl, personal communica-
tion). In the brain, iron and presumably
other metal ions are sequestered by ferritin.
Aluminum, Iron, and Ferritin
in the Brain
In humans, most ofthe iron is recycled and
very little is excreted. Therefore, the con-
centration oftotal iron in the human body
increases with age (29). In the male, it
increases from about 300 mg at age 20 to
25 years to about 1800 mg at age 80 to 90
years. In the female, the levels remains at
about 300 mg until the years of age 50 or
until menopause, and increase to about
1200 by the age of 80 to 90 years.
Significantly, a fetal brain has very little
iron or ferritin which stores it. In the adult
brain, a third of the total nonheme iron is
stored in ferritin (30). This protein is com-
posed of a total of 24 chains, heavy (H)
and light (L), of molecular weights of
21,000 and 19,000, respectively. A fully
saturated ferritin can store in its protein
shell up to 4500 molecules of iron as
Fe(III) hydroxyphosphate. Isoferritins vary-
ing in subunit composition exist in differ-
ent tissues. Ferritin binds several metal ions
in vitro and in vivo. Indeed, ferritin alu-
minum complex can be prepared in vitro,
and has been isolated from the brains of
two AD patients and from rats chronically
exposed for a year to 100 pM AlC13.6H20
in their drinking water (31). Our subse-
quent studies (unpublished data) showed
that ferritin isolated from two AD and one
normal brain had between 2 and 4 moles
of aluminum bound per mole of protein,
and one AD brain ferritin had 12.8 mole-
cules ofiron per mole offerritin. In all AD
brains, the concentration of ferritin was
consistently higher than in the controls.
Cochran and Chawtur (32) also observed
similar binding of aluminum to ferritin in
vitro. In contrast, Deadman et al. (33)
could not observe any difference in the alu-
minum bound to ferritin in normal and
AD brains, but consistent with earlier
observations (31) reported elevated levels of
ferritin in AD brains and they produced
aluminum ferritin complexes in vitro. We
observed that in vitro more aluminum
bound to holoferritin than to apoferritin
and that aluminum reduced the rate ofiron
uptake by ferritin (34).
To determine whether human brain
ferritin is chemically distinct from that
found in the liver, we undertook further
characterization of human brain ferritin
and its subunits. SDS-PAGE of ferritin
from normal or AD brain showed two
bands, H = 70%, L = 30%. However, iso-
electrofocusing on native ferritin showed
several bands of isoferritins (31). HPLC
chromatography (35) of human brain fer-
ritin from normal or AD tissues yielded a
cluster ofabout five heavy chains and pre-
dominantly only one light chain (Figure 2).
This appeared to have offered an explana-
tion for several isoforms of brain ferritin
resolving after isoelectrofocusing of the
native protein. To determine the differ-
ence, ifany, in the amino acid sequences of
H chains, we used a cDNA clone for fer-
ritin heavy chain from the liver and
screened the human brain cDNA libraries
from 11 week old fetal brain and from
adult normal and AD brains. The cDNAs
isolated from these sources were sequenced
by the "dideoxynucleotide" method. The
preliminary results schematically repre-
sented in Figure 3 showseveral things:
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Figure 5. Aluminum trichloride activates bovine pancreas a-chymotrypsin 2-fold at pH 6.5. The inset is a Lineweaver-
Burke plotwith a kb4,pp foraluminum trichloride of2 x 104 M. The shaded points are those used forthe Kap)determina-
tion. Standard assay conditions (39 were used, except 38 mM PIPES buffer, pH 6.5, was employed, the methanol
concentration was reduced to 3%, and calcium chloride was absent from the control assays. Fresh solutions of Sigma
enzyme were made daily, calibrated foractivity, and kept in dilute HCI on ice to prevent autolysis. One-min preincubations
of metal and enzyme were shown to be sufficient forfull activation. The synthetic substrate, benzoyl-tyrosine ethyl ester
(BTEE), was not precipitated or hydrolyzed bythe addition of aluminum trichloride alone. Different orders of addition did
notaffectactivation (39.
* none of these cDNAs were full length at
the 5' end.
* Northern blot analysis of the RNA (poly
A+) preparations from human liver, normal
adult and AD brain and 11-week-old fetal
human brains revealed the presence of two
transcripts of 1.4 kb and 1.1 kb for ferritin.
* The larger, 1.4 kb, is most abundantly
expressed in the brain, while its level of
expression in the liver is 10 times lower.
* the two transcripts are also expressed dif-
ferentially in other human tissues like kid-
ney, lungs, pancreas, heart, placenta, and
skeletal muscle.
* Comparison ofthe sequence showed that
the small transcript (1.1 kb) from the brain
was identical to that reported in the liver.
* The larger transcripts (1.4 kb) were
incomplete at the 5' end but contained a
279 sequence at 3'-UTR which is absent
from the smaller transcript.
* Computer comparisons of the 279 bp
sequence with the GenBank and EMBL
databases showed it to be 94.1, 62.5, and
58.9% homologous to the ferritin heavy
chain genomic sequences ofhuman, mouse
and rat, respectively (36). However, in all
these cases, it is reported to be the part of
the nontranscribed region.
* Northern blot hybridization and com-
puter analysis of the sequences of 1.4 kb
RNAs suggests that the 279 bp DNA frag-
ment corresponds to the mature ferritin
mRNA.
* It is especially noteworthy that the fetal
brain cDNA (1.6 kb) and the adult brain
>_
.r_
cDNA (1.4 kb) are identical at the 3'-UTR
and identical to the available sequence of
the coding region.
* The fetal brain cDNA is identical to the
liver (1.1 kb) cDNA in the coding region
and only a part of 5' UTR. However, the
presence of a stretch of 28 nucleotide
sequence in the S'UTR corresponding to
the iron responsive element in the liver
mRNA could not be detected in the fetal
brain mRNA. Instead, a different =54 nt
sequence is observed. Whether this belongs
to the ferritin mRNA or to a totally unre-
lated gene and the role of279 bp sequence
in the regulation of ferritin synthesis is
under investigation.
Aluminum and Plaque
Formation
Presence of plaques in an AD brain first
discovered by Alzheimer in 1907 (37) has
survived the test oftime and is now consid-
ered a histopathological benchmark of the
AD brain. The plaques are aggregates of a
39 to-42-amino-acid-long peptide (J-AP)
produced by the proteolysis of a family of
a-amyloid precursor proteins (P-APPs).
Serine proteases are suggested to be
involved in this processing. Part of the
P-A4 segment of )-APP is lodged in the
plasma membrane that separates cytoplasm
from the extracellular region (Figure 4).
These proteins are also found in other nor-
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Figure6.Aluminum protects a-chymotrypsin from inhibition bybPTI and BX-9 to a similar extent. The abscissa givesthe
concentration of either bPTI or BX-9 inhibitor. The inset shows an enlargement of the inhibition curve for the control
enzyme (1.75 x 1e M)with bPTI (m) orBX-9(A). In the presence of5 x10e M Al, the inhibition constant(K,)for bPTI (o)
and for BX-9(A) were approximately 100-fold higher. The K1 values were calculated as published bySinha etal. (41). The
OrWofiles of the control curves were similar to those previously reported, but not all of the BX-9 reacted to form
inhibitor-protease complex. This was also seen in part in the original work on BX-9 (41). This may simply relate to the
presence oftheP-galactosidase portions ofthe fusion protein. However, an altered binding mechanism atthe acidic pH
cannotbe excluded(39.
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Figure 7. Working model showing the role ofaluminum, iron, acidic pH, and proteases and their inhibitors in plaque for-
mation (39).
mal or AD tissues. The 2 f-APPs that con-
tain 750 and 771 amino acids also contain
a 56-amino-acid-long segment whose
sequence is 60% homologous to the well-
known bovine pancreatic trypsin inhibitor
(bPTI). This led to the suggestion that
deregulation ofthe interaction between the
serine protease(s) and their substrates (I-
APP) leads to P-AP and their subsequent
aggregation into plaques. Although any
physiological role of 3-APPs or ,B-AP is
unknown, they are believed to be involved
in the etiologyofAD (2).
At physiological pH, calcium (Ca) ions
(20 mM) stabilize serine proteases against
autolysis. We observed that in vitro at pH
6.5, 200 PM AlCl3.6H20 (total concentra-
tion) activated a-chymotrypsin 2-fold
(Figure 5). The activation was immediate
and reversible by dilution. One mole of
aluminum bound per mole ofenzyme (Hill
plot) and neither Cl, nor Na,+ nor Fe(III)
affected a-chymotrypsin activity (data not
shown). Ca(II) also activated the enzyme,
yet the KM(app) was 10-fold higher. Metal
buffers are routinely used to assure a steady
supply of a free metal ion. In the presence
of an appropriate concentration of chela-
Environment
Al (inert)
ta
tors such as ethylenediaminetetracetic acid
or nitrilotriacetate the concentration of
A1(III) can bevaried between 10 9 to 103M
(38). However, when these chelators were
employed in the assay system, the activat-
ing effect ofaluminum was abolished (39).
This strongly suggests, although it does not
prove, that hydroxylated polynuclear
species could be responsible for the activa-
tion of the enzyme. Thus, high focal con-
centrations of probably polynuclear
aluminum deposits discovered in the brains
ofpatients with AD may be physiologically
significant (39).
Figure 6 shows the effect of bPTI or
the bPTI-like segment of P-APPs on the
activity ofa-chymotrypsin and compares it
with that of the aluminum-activated
enzyme. As seen, aluminum dramatically
protected a-chymotrypsin against the inhi-
bition by bPTI or the BX-9 fusion protein
(41) which contains the bPTI-like segment
of P-APP inserted into P-galactosidase.
Aluminum reduced the affinity of either
inhibitor for the enzyme by 100 fold (KI
without Al = 3.7 xIO-10 M, K1(Al) = 4.6 x
0-8 M).
il Stress
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Figure & Schematicmodel ofpossible interactions and ill effectsofiron and aluminum in brain metabolism.
Aluminum also activated trypsin by
140% with a similar K(app) but produced
only a 15-fold decrease in the binding of
bPTI (data not shown). In addition to a-
amyloid peptide(s), AD plaques also con-
tain a-i-antichymotrypsin. Aluminum
protected against inhibition by a-i-
antichymotrypsin, but the change in K, was
only about 10-fold (40).
The above results were obtained with
synthetic substrates. To verify whether the
results hold true for natural substrates, we
studied limited proteolysis oftransferrin by
a-chymotrypsin in the presence of
AICI .6H20. Indeed, aluminum produced
a 2-?old increase in the rate of proteolysis
of transferrin (KMAl(app)-2.1 x 104- M).
Finally, 100,000 g supernatants of brain
homogenates at pH 6.5 also showed a 2.8-
fold increase in the rate of hydrolysis of
BTEE in the presence of 5 x 10-4 M
AIC13.6H20 (39).
Role of Iron in Plaque
Formation
Interaction of metal ions such as Fe(II)
with oxygen produce oxygenated free radi-
cals (42). These radicals oxidatively modify
proteins and make them more susceptible
to proteolysis (43), damage DNA, and per-
oxidize lipids (42). Aluminum enhances
the lipid peroxidation oferythrocyte mem-
branes initiated by iron. The rate of this
lipid peroxidation is greater at acidic pH
(44). Acidic pH also accelerates the rate of
the release of iron from ferritin (21) and
favor aggregation of 1-AP (45). More
recently Dyrks et al. (46) reported that in
vitro, the cross-linking of f-AP, which
causes the formation of insoluble plaques,
is enhanced by oxygenated free radicals
produced in the presence of a metal ion
such as iron. Localized acidosis in the brain
has been reported during ischemia, and
hypoxia, and in AD patients (47-49).
Figure 7 shows how these factors can con-
tribute to plaque formation.
The role of aluminum and iron in
deregulating brain metabolism discussed
above is summarized in Figure 8. Almost
all the changes observed in AD brain are
quantitative and not qualitative. Thus,
although the presence of increased alu-
minum in AD brain is generally confirmed,
in one recent report its presence in AD
(senile) plaques has been attributed to
experimental artifact (50). Similarly, the
presence of an increased concentration of
ferritin in AD brain reported earlier
(31,33) and its localization in neuritic
plaques ofAD patients (51) has been con-
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firmed, but its association with Al was not
seen in several AD brains (33). Most
reports show that familial cases ofAD once
considered due to genetic mutations in the
AD-gene in chromosome 21 may also arise
from mutations in chromosomes 19 and 14
(52). The amyloid plaque unique for AD
brains is observed by histopathologic exam-
ination of the brains of diseased patients
and, therefore, has been considered by
many as the end result, rather than the
cause, ofAD. The P-APPs exist in normal
individuals also, but their biological func-
tion is unknown. Finally, even in the famil-
ial AD, identical afflicted twins are not
aflicted by AD simultaneously. Similarly,
not every individual exposed to elevated
levels of environmental aluminum suffers
from AD. It therefore appears that AD
probably results from the iron-and alu-
minum-mediated colocalization of meta-
bolic errors accumulating in specific areas
of the brain (Figure 7). Clearly, the reac-
tions shown do not have to occur in the
order given. For example, large concentra-
tions of i-AP can be produced with an
active protease and sufficiently high con-
centrations of ,-APPs. Aluminum, iron,
oxygen, and an acidic pH can help achieve
that level ofP-AP faster and at lower con-
centration of P-APPs by activating the
protease, and permitting its function
despite the presence of the PPTI-like
inhibitor of ,-APPs and crosslinking P-
AP. Similarly, the role of aluminum in
deregulating various metabolic reactions
in Figure 8 (12) as well as numerous oth-
ers (10) could occur only ifthe local con-
centrations ofaluminum and iron are suf-
ficiently high. The same is true for the ill
effects ofunsequestered iron.
Although the data presented above and
summarized in Figures 7 and 8 have been
obtained in vitro and need to be verified
in vivo, recent reports seem to support the
postulate that indeed iron and aluminum
contribute to the onset of AD.
Accordingly, epidemiologic studies of
McLachlan et al. (53) reported partial
reliefagainst AD by desferrioxamine. This
compound was first used against dialysis
dementia caused by aluminum toxicity. It
is an effective chelator for aluminum as
well as iron. Thus, the observed relief
against AD (53) may well be due to the
removal ofboth these neurotoxins.
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